Related Experiment Video
Updated: Jun 24, 2026

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
Published on: January 7, 2019
Is it safe to switch from stavudine to zidovudine after developing symptomatic hyperlactatemia?
Barbara Castelnuovo1, Agnes Nanyonjo, Moses Kamya
1Infectious Diseases Institute, Kampala, Uganda. bcastelnuovo@idi.co.ug
Introduction:
In resource limited settings patients on antiretroviral treatment who develop stavudine induced hyperlactatemia are often switched to zidovudine on the basis of published studies that demonstrate that this agent can be a safe alternative.
Case Report:
We describe here a case of a 60 year old female that experienced a relapse of symptomatic hyperlactatemia after being switched from stavudine to zidovudine and how the case was managed at the Infectious Diseases Institute, Kampala, Uganda.
Discussion:
This case shows that switching to zidovudine potentially can lead to a hyperlactatemia relapse. Therefore we recommend close follow up for patients that are switched from stavudine to zidovudine and, in case lactate measurement is not possible, free programs should provide safer drugs such as abacavir and tenofovir for patients that develop hyperlactatemia.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Mania and Antimanic Drugs: Overview

